Bianca Lăcrimioara Petca

Mrs. Bianca Lăcrimioara Petca


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background/Objectives: Type 2 diabetes mellitus (T2DM) is characterized by overlapping cardiovascular, renal, metabolic, and hepatic-risk abnormalities. We characterized this integrated phenotype, examined SCORE2-Diabetes gradients, and assessed whether routinely available variables could classify established atherosclerotic cardiovascular disease (ASCVD). Methods: This cross-sectional study included 232 consecutive adults with T2DM. SCORE2-Diabetes tertiles in the full cohort were analyzed descriptively, and a sensitivity analysis was restricted to participants aged 40–69 years without established ASCVD or severe target-organ damage. FIB-4 was recalculated from age, aspartate aminotransferase, alanine aminotransferase, and platelet count. Elastic-net logistic regression, random forest, and gradient boosting were evaluated using nested stratified five-fold cross-validation, with all preprocessing and hyperparameter tuning confined to the training folds. Results: Established ASCVD was present in 49 participants (21.1%), corresponding to 4.45 events per candidate predictor. The SCORE2-Diabetes-eligible sensitivity subgroup included 118 participants (50.9%); 72.9% were in the ≥20% 10-year-risk category. FIB-4 was available for 231 participants (median 1.26 [IQR 0.96–1.80]). Nested cross-validated ROC AUCs were 0.675 (95% CI 0.582–0.763) for elastic-net logistic regression, 0.670 (0.581–0.754) for random forest, and 0.674 (0.589–0.752) for gradient boosting; balanced accuracies were 65.4%, 62.8%, and 56.2%, respectively. Conclusions: The cohort had a high and heterogeneous cardio–renal–metabolic burden. SCORE2-Diabetes findings from the full cohort are descriptive because the score is not intended for patients with established ASCVD or severe target-organ damage. The machine-learning models showed only modest, internally validated discrimination and are not suitable for clinical deployment without larger prospective cohorts and external validation.

26 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Type 2 diabetes mellitus (T2DM) is clinically heterogeneous, and routinely available renal, inflammatory, and hepatic measures may add information beyond glycemic assessment. Methods: Among 811 screened adults, 809 had a standardized baseline assessment and six-month follow-up; two were excluded because a required baseline clustering variable was missing, leaving 807 complete cases for phenotype derivation. Twelve-month data were available for 320 participants. Nine baseline variables were standardized, with UACR and CRP analyzed after ln(x + 1) transformation. Candidate two- to six-cluster solutions were assessed using silhouette, Calinski–Harabasz, and Davies–Bouldin indices, 200 bootstrap resamples, and a consistent-transformation sensitivity analysis. Longitudinal outcomes were evaluated using generalized estimating equations including time, phenotype, and their interaction. Results: The final stored four-cluster solution comprised a comparatively favorable-profile phenotype (n = 294), a cardiorenal–fibrotic phenotype (n = 239), an inflammatory–metabolic phenotype (n = 141), and a severe hyperglycemic–obesity phenotype (n = 133). Internal separation was modest (silhouette 0.118; Calinski–Harabasz 87.6; Davies–Bouldin 2.118), bootstrap agreement was moderate (median adjusted Rand index 0.445), and the consistent ln(x + 1) sensitivity solution showed substantial agreement with the stored assignment (adjusted Rand index 0.776). Significant phenotype-by-time interactions were observed for HbA1c, BMI, TyG, triglycerides, UACR, eGFR, FIB-4, and CRP after false-discovery-rate correction, but not for LDL cholesterol. Baseline characteristics did not differ detectably between participants with and without twelve-month follow-up after correction. Marked treatment changes occurred by T2, particularly increased use of GLP-1 receptor agonists and SGLT2 inhibitors. Conclusions: The four phenotypes provide an exploratory multidimensional description of this cohort. Longitudinal differences should not be attributed to phenotype biology alone because regression to the mean and treatment intensification are plausible contributors; external validation remains necessary.

21 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Contemporary management of type 2 diabetes mellitus (T2DM) has shifted from a glucose-centered approach toward integrated cardio-renal–metabolic protection. Although sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and intensive lipid-lowering therapies have demonstrated substantial cardiovascular and renal benefits, implementation in routine outpatient care and the burden of persistent residual risk remain insufficiently characterized in Romania. Objectives: We aimed to evaluate routine-care pharmacological treatment patterns, identify residual cardio-renal–metabolic risk despite ongoing therapy, determine independent correlates of persistent adverse outcomes, and explore potential therapeutic gaps in adults with T2DM. Methods: This cross-sectional observational study included 232 unique adults with T2DM attending a specialized outpatient diabetes clinic in Romania between 1 October 2024 and 19 February 2026. One eligible outpatient record per participant was analyzed; when multiple records were available, the earliest eligible record in the exported dataset was used as the index visit. No a priori sample-size calculation was performed. Pharmacological therapies, cardiovascular and renal phenotypes, metabolic biomarkers, and clinical outcomes were extracted from routinely collected electronic medical records. Residual risk was evaluated using glycemic, lipid, renal, obesity, and blood-pressure targets. Multivariable logistic regression analyses identified independent correlates of persistent cardio-metabolic abnormalities. An exploratory cumulative residual-risk count was constructed by summing seven clinically relevant uncontrolled risk factors. Results: Biguanides were the most frequently prescribed glucose-lowering agents (53.0%), followed by SGLT2 inhibitors (44.8%), insulin (32.3% of the total cohort), GLP-1 receptor agonists (15.5%), and DPP-4 inhibitors (14.7%). Statins were prescribed to 48.7% of participants. SGLT2 inhibitor use did not differ significantly according to established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease phenotypes, whereas GLP-1 receptor agonists were prescribed more frequently in participants with obesity (22.0% vs. 7.6%, p = 0.003). Clinically important residual risk persisted across all treatment groups. Among SGLT2 inhibitor users, 57.3% had HbA1c ≥ 7%, while 27.9% remained albuminuric. Among insulin-treated participants, 84.0% had HbA1c ≥ 7%; reduced eGFR and albuminuria were also more frequent than among non-users. Despite statin therapy, 33.6% of treated participants continued to exhibit LDL cholesterol ≥ 100 mg/dL. In multivariable logistic regression, insulin therapy was associated with higher odds of HbA1c ≥ 7% (adjusted odds ratio [aOR] 7.41, 95% confidence interval [CI] 3.50–15.65), while SGLT2 inhibitor therapy was associated with lower odds of albuminuria (aOR 0.54, 95% CI 0.30–0.95). Absence of statin-containing therapy was associated with higher odds of LDL cholesterol ≥ 100 mg/dL (aOR 6.01, 95% CI 3.38–10.66). Absence of statin-containing therapy was associated with higher odds of residual LDL cholesterol ≥ 100 mg/dL (aOR 4.21, 95% CI 2.34–7.58). Seventy-two percent of participants presented at least three persistent cardio-renal–metabolic abnormalities, while 24.2% exhibited five or more. More than half of participants with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease were not receiving either an SGLT2 inhibitor or a GLP-1 receptor agonist. Conclusions: Significant residual cardio-renal–metabolic risk persists in adults with T2DM despite use of contemporary pharmacological therapies. Disease severity markers and treatment exposure were associated with persistent adverse outcomes, but the cross-sectional design does not establish causality. The study identified potentially modifiable therapeutic gaps among patients with established cardiovascular and renal disease. Comprehensive and repeatedly reassessed cardio-renal–metabolic management, integrating pharmacological optimization with individualized risk stratification, may improve implementation of guideline-directed therapy and reduce long-term complications in routine clinical practice.

16 September 2026 in Medicina
Verified
Journal Article
Open access
PDF file
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background and Objectives: Current self-management behavior may not reflect the long-term exposures that led to established complications in people with type 2 diabetes (T2D). To assess whether Diabetes Self-Management Questionnaire (DSMQ) scores were associated with the number of documented diabetes-related and cardiovascular conditions and whether the finding was robust to alternative outcome constructions. Materials and Methods: This single-center cross-sectional reanalysis included 262 adults with T2D. The DSMQ was re-calculated from item-level responses. The primary outcome was an unweighted count of seven database-recorded conditions. Spearman correlation and multivariable Poisson regression with HC3 robust standard errors were used. Sensitivity analyses excluded heart failure, separated microvascular and cardiovascular counts, and substituted estimated glomerular filtration rate <60 mL/min/1.73 m2 for the recorded chronic kidney disease field. Results: Median DSMQ Sum Scale was 5.10 (IQR 3.13–7.08), and median condition count was 3 (IQR 2–3). No evidence of an unadjusted association was identified (ρ = −0.056; p = 0.368). In the adjusted model (n = 260), the DSMQ estimate was IRR 0.988 per point (95% CI 0.962–1.014; p = 0.355). The result remained nonsignificant after excluding heart failure (IRR 0.993; 95% CI 0.960–1.027), for the microvascular count (IRR 0.993; 95% CI 0.964–1.024), and for the cardiovascular count including heart failure (IRR 0.980; 95% CI 0.945–1.015). Pearson dispersion was 0.587, providing no evidence of overdispersion. Conclusions: No evidence of an association between current DSMQ-measured self-management and the number of recorded conditions was identified in this cohort. The result does not demonstrate equivalence and does not imply that sustained self-management is unrelated to long-term complication risk. In practice, contemporary DSMQ scores should guide cur-rent education and support needs, not be used as a proxy for historical com-plication exposure.

19 September 2026 in Diseases
Verified
Journal Article
Open access
PDF file
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Diabetes self-management is essential for type 2 diabetes care, but cross-sectional associations may be distorted when questionnaire scores are incorrectly derived or converted into arbitrary categories. We evaluated clinical and sociodemographic correlates of the continuous Diabetes Self-Management Questionnaire (DSMQ) total score in a secondary analysis of an outpatient clinical database. Methods: The analysis included 262 adults with type 2 diabetes recruited between 1 November 2025 and 1 May 2026. DSMQ total and subscale scores were independently recalculated from the 16 item-level responses using the published scoring algorithm. The primary analysis retained the DSMQ score as a continuous outcome. The database provided a participant-level count of documented glucose measurements > 250 mg/dL. This operational count was not treated as a standardized clinical event or severity category; individual measurement timestamps, participant-specific observation duration, and the total number of glucose measurements were unavailable. Results: The recalculated DSMQ score was 5.26 ± 2.35 (median 5.10; interquartile range 3.12–7.08). Among 261 participants with an interpretable sex code, 144 (55.2%) were women. In univariable analyses, lower DSMQ scores were concurrently associated with longer diabetes duration, a higher recorded severe-hyperglycemia count, higher HbA1c, and higher fasting glucose. In the adjusted model (n = 261), the recorded severe-hyperglycemia count remained negatively associated with DSMQ score (adjusted coefficient −0.412 points per recorded episode; 95% confidence interval −0.621 to −0.203; p < 0.001). Individualized versus hospital-based education was not independently associated with the corrected score. A beta-regression sensitivity analysis produced a concordant direction of association (coefficient −0.152 on the logit mean scale; p < 0.001). The linear model explained 17.2% of observed variance (adjusted R2 = 0.136), with an optimism-corrected R2 of 0.099. Conclusions: The recorded severe-hyperglycemia count was a concurrent correlate of lower DSMQ score. Because the study is cross-sectional and glucose-measurement counts were preaggregated without observation-time or monitoring-frequency data, the findings do not establish temporal direction, causality, or individual-level clinical prediction. Item-level score verification and continuous-outcome analysis materially changed the interpretation of the dataset.

12 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
PPPaula Alexandra Popovici
Paula Alexandra Popovici
AIAndreea Diana Igna
Andreea Diana Igna
BPBianca Lăcrimioara Petca
Bianca Lăcrimioara Petca
CCCorina Cinezan
Corina Cinezan
TGTIMEA CLAUDIA GHITEA
TIMEA CLAUDIA GHITEA
MPMihaela Simona Popoviciu
Mihaela Simona Popoviciu
Background: Accurate scoring is essential when patient-reported self-management instruments are related to biochemical outcomes. The principal contribution of this study was to reconstruct and audit Diabetes Self-Management Questionnaire (DSMQ) scores from item-level data before reassessing their cross-sectional association with glycemic control. Methods: We performed a cross-sectional secondary analysis of a clinical database of adults with type 2 diabetes. One non-patient header row was removed. Because 12 observation-sheet identifiers occurred twice and visit dates were unavailable, all 24 records carrying repeated identifiers were excluded from the prespecified primary analysis, leaving 238 records. Negatively keyed DSMQ items were reverse-scored, and total and subscale scores were transformed to a 0–10 scale according to the original algorithm. Associations with HbA1c were assessed using Spearman correlation, exploratory ROC analysis, and multivariable linear regression with HC3 robust standard errors. Results: HbA1c was available for 237 records; mean age was 64.18 years (SD 11.14), 56.1% of records with valid sex coding were female, and mean HbA1c was 7.81% (SD 1.94). The corrected DSMQ total score was 5.19 (SD 2.36). DSMQ total score correlated inversely with HbA1c (ρ = −0.467, bootstrap 95% CI −0.572 to −0.350; p < 0.001). In the adjusted model (n = 236), each one-point higher DSMQ total score was associated with a 0.254 percentage-point lower HbA1c (regression coefficient = −0.254, 95% CI −0.344 to −0.163; p < 0.001). Sensitivity analyses using all records or first/last repeated-record rules produced similar estimates. Conclusions: Correctly scored DSMQ results showed a moderate, independent cross-sectional association with HbA1c. The corrected analysis did not demonstrate excellent discrimination, and the cross-sectional data cannot support causal or predictive claims. Prospective studies with verified unique participants and clearly documented data provenance are needed.